Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2025-01095 | Registry Identifier | CTRP (Clinical Trial Reporting Program) | |
| 24-003478 | Other Identifier | Mayo Clinic in Rochester | |
| HT9425-24-1-0619 | Other Grant/Funding Number | Department of Defense |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluates a novel laboratory method to study how certain bone marrow cells in the body take up nutrients from their environment.
PRIMARY OBJECTIVE:
I. Evaluate differences in the amount of extracellular uptake of glucose and amino acids (AAs) between pre-malignant clonal plasma cells (cPCs) and polyclonal plasma cells (pPCs).
OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups.
GROUP I: Patients undergo blood collection and bone marrow aspiration as part of their standard care and have their medical records reviewed on study.
GROUP II: Healthy volunteers undergo blood collection and bone marrow aspiration on study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Observational Group I | Patients undergo blood collection and bone marrow aspiration as part of their standard care and have their medical records reviewed on study. |
| |
| Observational Group II | Healthy volunteers undergo blood collection and bone marrow aspiration on study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Non-Interventional Study | Other | Non-interventional study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Extracellular uptake of glucose and amino acids (AAs) between pre-malignant clonal plasma cells (cPCs) and polyclonal plasma cells (pPCs) | Assessed by evaluating blood and bone marrow aspirate samples for mean 13Carbon (13C) percentage enrichment of the mass isotopomers of interest of at least 6 (i.e. the difference between a mean 13C percentage enrichment of a particular mass isotopomer is 12% in the MGUS group and 6% in the healthy participant group or vice versa) using a 2-group t-test with a 2-sided significance level of 0.01. | Up to 30 days |
Not provided
Not provided
Inclusion Criteria:
All Participants:
MGUS Cohort:
Exclusion Criteria:
All Participants:
Not provided
Not provided
Not provided
Patients with a diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and healthy volunteers
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wilson I. Gonsalves, MD | Mayo Clinic in Rochester | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | United States |
Not provided
| Label | URL |
|---|---|
| Mayo Clinic Clinical Trials | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008998 | Monoclonal Gammopathy of Undetermined Significance |
| ID | Term |
|---|---|
| D006942 | Hypergammaglobulinemia |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood and bone marrow
| D010265 | Paraproteinemias |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |